The purchase price, and that is confidential and was negotiated for a maximum of 300 million doses, is somewhat lower than the $19.50 a picture the United States agreed to buy a very first shipment of hundred million doses of the identical vaccine, in series with what Reuters claimed in November.
The EU file dated Nov. 18 was circulated internally right after the EU announced the supply offer of its with Pfizer and its German partner BioNTech on Nov. eleven.
The EU drug regulator is expected to decide on Monday on approval for the Pfizer vaccine after the shot was authorised in a few countries, like Britain as well as the United States.
On Thursday Belgian state secretary with the budget Eva De Bleeker published on Twitter a dinner table with price tags Belgium will pay pharmaceutical companies for their COVID 19 vaccines. She retracted the post shortly after publishing.
In that table the Pfizer vaccine was suggested as costing Belgium 12 euros ($14.6) a dose, top many to believe this was the total fee agreed by the EU.
Other vaccines in the family table were furthermore shown with prices lower compared to prices disclosed by EU sources.
“There is for sure a total price and a price after delivery,” an EU official required in talks with vaccine creators told Reuters when made to clarify the big difference between the Belgian and EU rates.
A spokesman for De Bleeker declined to comment on Monday, citing confidentiality needs, but pointed to what De Bleeker told the Belgian parliament previous week. In that public hearing, De Beeker said Belgium’s budgeted price tags were still partial.
Under EU advanced purchase deals for COVID 19 vaccines, the bloc concurs upfront payments with businesses to secure doses before they’re approved. Following approvals, EU governments can pay the rest to get reserved doses.
The EU hasn’t revealed the initial transaction agreed with Pfizer.
But, it mentioned in October which it paid about 1 billion euros inside downpayments to AstraZeneca, Sanofi and Johnson and Johnson for their shots, with a further 1.45 billion euros budgeted for initial payments to Pfizer-BioNTech, Moderna and Curevac.
It has since agreed supply deals with all 6 businesses and is negotiating a seventh arrangement with Novavax.